Wealth Enhancement Advisory Services
PRME icon

Wealth Enhancement Advisory Services’s Prime Medicine PRME Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1K Sell
15,096
-22,585
-60% -$75K ﹤0.01% 3902
2026
Q1 		$125K Buy
37,681
+11,583
+44% +$44.1K ﹤0.01% 3271
2025
Q4 		$96.6K Sell
26,098
-680
-3% -$3.02K ﹤0.01% 3436
2025
Q3 		$157K Buy
26,778
+771
+3% +$3.13K ﹤0.01% 3218
2025
Q2 		$80.9K Buy
26,007
+13,777
+113% +$21.2K ﹤0.01% 3171
2025
Q1 		$24.3K Buy
+12,230
New +$31.2K ﹤0.01% 2905

Other funds holding PRME

MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
SWM
Shelton Wealth Management Fort Worth, Texas $255M AUM 34.47% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Wealth Enhancement Advisory Services's PRME Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Prime Medicine (PRME) stake by 60% in Q2 2026, selling an estimated $75K and leaving 15,096 shares worth $57.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Wealth Enhancement Advisory Services first reported a position in PRME in Q1 2025 and has held it in 6 quarters since. The position peaked at $157K in Q3 2025. 8 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Wealth Enhancement Advisory Services held 15,096 shares of Prime Medicine worth $57.1K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 22,585 Prime Medicine shares in Q2 2026, an estimated $75K.
  • Prime Medicine made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3902 holding.
  • Wealth Enhancement Advisory Services first reported a position in Prime Medicine in Q1 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Prime Medicine position peaked at $157K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.